JP2011527986A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011527986A5 JP2011527986A5 JP2011503236A JP2011503236A JP2011527986A5 JP 2011527986 A5 JP2011527986 A5 JP 2011527986A5 JP 2011503236 A JP2011503236 A JP 2011503236A JP 2011503236 A JP2011503236 A JP 2011503236A JP 2011527986 A5 JP2011527986 A5 JP 2011527986A5
- Authority
- JP
- Japan
- Prior art keywords
- ene
- triol
- ethynylandrost
- crystalline
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000001757 thermogravimetry curve Methods 0.000 claims description 15
- 230000009102 absorption Effects 0.000 claims description 13
- 238000010521 absorption reaction Methods 0.000 claims description 13
- 239000012453 solvate Substances 0.000 claims description 12
- 150000008064 anhydrides Chemical class 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 10
- 238000001237 Raman spectrum Methods 0.000 claims description 9
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 claims description 8
- 230000004968 inflammatory condition Effects 0.000 claims description 8
- 238000001228 spectrum Methods 0.000 claims description 8
- 230000004580 weight loss Effects 0.000 claims description 8
- 238000001069 Raman spectroscopy Methods 0.000 claims description 7
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 208000030159 metabolic disease Diseases 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000032843 Hemorrhage Diseases 0.000 claims description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- 201000001421 hyperglycemia Diseases 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 2
- 208000034158 bleeding Diseases 0.000 claims description 2
- 230000000740 bleeding effect Effects 0.000 claims description 2
- 238000004455 differential thermal analysis Methods 0.000 claims description 2
- 238000004821 distillation Methods 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 claims description 2
- 230000000877 morphologic effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000002411 thermogravimetry Methods 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4224008P | 2008-04-03 | 2008-04-03 | |
| US61/042,240 | 2008-04-03 | ||
| PCT/US2009/039567 WO2009124300A2 (en) | 2008-04-03 | 2009-04-03 | Solid state forms of a pharmaceutical |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014242946A Division JP2015042686A (ja) | 2008-04-03 | 2014-12-01 | 医薬の固体状態形態 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011527986A JP2011527986A (ja) | 2011-11-10 |
| JP2011527986A5 true JP2011527986A5 (https=) | 2012-05-24 |
Family
ID=41136126
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011503236A Withdrawn JP2011527986A (ja) | 2008-04-03 | 2009-04-03 | 医薬の固体状態形態 |
| JP2014242946A Pending JP2015042686A (ja) | 2008-04-03 | 2014-12-01 | 医薬の固体状態形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014242946A Pending JP2015042686A (ja) | 2008-04-03 | 2014-12-01 | 医薬の固体状態形態 |
Country Status (13)
| Country | Link |
|---|---|
| US (9) | US8252947B2 (https=) |
| EP (1) | EP2273994B1 (https=) |
| JP (2) | JP2011527986A (https=) |
| KR (1) | KR101545300B1 (https=) |
| CN (1) | CN102215845A (https=) |
| AU (1) | AU2009231589B2 (https=) |
| CA (1) | CA2728889C (https=) |
| DK (1) | DK2273994T3 (https=) |
| ES (1) | ES2562069T3 (https=) |
| HU (1) | HUE028337T2 (https=) |
| PL (1) | PL2273994T3 (https=) |
| PT (1) | PT2273994E (https=) |
| WO (1) | WO2009124300A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2273994T3 (en) * | 2008-04-03 | 2016-02-01 | Neurmedix Inc | PHARMACEUTICAL FORMS OF A MEDICINE |
| CN102046647A (zh) | 2008-06-06 | 2011-05-04 | 哈博生物科学公司 | 制备17-炔基-7-羟基甾族化合物和相关化合物的方法 |
| US20120220560A1 (en) * | 2010-12-17 | 2012-08-30 | White Steven K | Steroid tetrol solid state forms |
| CN103768071B (zh) * | 2012-10-23 | 2016-08-17 | 中国医药工业研究总院 | 一种治疗糖尿病的口服制剂 |
| WO2019041078A1 (en) * | 2017-08-28 | 2019-03-07 | Zhejiang Jiachi Pharmaceutical Development Ltd. | ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES |
| JP2024519079A (ja) * | 2021-05-18 | 2024-05-08 | バイオビー・インコーポレイテッド | 神経変性状態の治療のための組成物 |
| WO2024054452A1 (en) * | 2022-09-06 | 2024-03-14 | Biovie Inc. | Methods for the treatment of mild cognitive impairment |
| CN120484042B (zh) * | 2025-05-16 | 2026-01-30 | 中国人民解放军军事科学院军事医学研究院 | 一种he3286的合成方法 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4329366A (en) * | 1979-11-08 | 1982-05-11 | Johnson & Johnson Products, Inc. | Topical acylaminophenols |
| US4898694A (en) | 1987-11-25 | 1990-02-06 | Schwartz Arthur G | 17-Hydroxy-steroids |
| DE3801229A1 (de) | 1988-01-18 | 1989-07-27 | Krupp Polysius Ag | Mahlverfahren sowie mahlanlage |
| JP2642486B2 (ja) | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
| US5641766A (en) | 1990-08-29 | 1997-06-24 | Humanetics Corporation | UP-regulation of immune system with Δ 5-Androstenes |
| US5292730A (en) | 1990-08-29 | 1994-03-08 | Humanetics Corporation | Modulation of immune system with Δ5-androstenes |
| AU647528B2 (en) | 1990-08-29 | 1994-03-24 | Humanetics Corporation | Treatment process for promoting weight loss employing a substituted delta5-androstene |
| US5271944A (en) | 1991-04-05 | 1993-12-21 | Biofor, Ltd. | Pharmacologically enhanced formulations |
| US5922701A (en) | 1992-05-01 | 1999-07-13 | University Of Utah Research Foundation | Method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue |
| US5424077A (en) | 1993-07-13 | 1995-06-13 | Church & Dwight Co., Inc. | Co-micronized bicarbonate salt compositions |
| TW369521B (en) | 1993-09-17 | 1999-09-11 | Smithkline Beecham Corp | Androstenone derivative |
| US5455049A (en) | 1995-01-04 | 1995-10-03 | Ascent Pharmaceuticals, Inc. | Terfenadine oral powder |
| US5859000A (en) | 1995-06-07 | 1999-01-12 | University Of Utah Research Foundation | Method for reducing mast cell mediated allergic reactions |
| US5869709A (en) | 1997-05-07 | 1999-02-09 | Humanetics Corporation | Process for effecting allylic oxidation |
| US6686486B1 (en) | 1997-05-07 | 2004-02-03 | Padma Marwah | Process for effecting allylic oxidation |
| ZA986614B (en) | 1997-07-25 | 1999-01-27 | Gilead Sciences | Nucleotide analog composition |
| AU3088799A (en) | 1998-03-18 | 1999-10-11 | Humanetics Corporation | Process for effecting allylic oxidation using dicarboxylic acid imides and chromium reagents |
| US20080015174A1 (en) * | 1998-11-24 | 2008-01-17 | Reading Christopher L | Metabolic Disease Treatments |
| US20030083231A1 (en) | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
| US20070129282A1 (en) * | 1998-11-24 | 2007-06-07 | Ahlem Clarence N | Pharmaceutical treatments and compositions |
| US20060079492A1 (en) | 1999-10-25 | 2006-04-13 | Ahlem Clarence N | Compositions and treatment methods |
| US20030060425A1 (en) | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
| US6667299B1 (en) | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
| US7045513B1 (en) | 1999-03-18 | 2006-05-16 | Genelabs Technologies, Inc. | DHEA composition and method |
| PT1955700E (pt) | 1999-09-30 | 2011-05-04 | Harbor Biosciences Inc | Tratamento terap?utico de doen?as associadas ao receptor de androg?nios |
| CA2388939C (en) | 1999-10-25 | 2009-06-09 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatments for blood cell deficiencies |
| US6274746B1 (en) | 2000-08-30 | 2001-08-14 | Padma Marwah | Process for allylic oxidation using metal hypochlorite and alkyl hydroperoxide |
| US7867990B2 (en) | 2000-12-14 | 2011-01-11 | Ortho-Mcneil Pharmaceutical, Inc. | Steroid hormone products and methods for preparing them |
| FR2820745A1 (fr) | 2001-02-14 | 2002-08-16 | Oreal | Procedes de preparation de la 7alpha-hydroxy- dehydroepiandrosterone |
| AU2002352726A1 (en) * | 2001-11-15 | 2003-06-10 | Galileo Laboratories, Inc. | Formulations and methods for treatment or amelioration of inflammatory conditions |
| US7372941B2 (en) | 2002-08-06 | 2008-05-13 | Ssci, Inc. | System and method for matching diffraction patterns |
| EP1678484A2 (en) | 2003-10-27 | 2006-07-12 | SSCI, Inc. | Method for monte carlo indexing of powder diffraction data |
| US20070243620A1 (en) | 2004-02-24 | 2007-10-18 | Simon Bates | Analysis and Screening of Solid Forms Using the Atomic Pair Distribution Function |
| AU2005330504B2 (en) * | 2004-09-29 | 2010-10-28 | Harbor Biosciences, Inc. | Steroid analogs and characterization and treatment methods |
| US20060073099A1 (en) | 2004-10-01 | 2006-04-06 | Frincke James M | Treatment screening methods |
| US20060211604A1 (en) * | 2004-11-26 | 2006-09-21 | The Brigham And Women's Hospital, Inc. | Methods for treating inflammatory disorders using regulators of microvessel dilations |
| US7964604B2 (en) | 2005-02-18 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Bifeprunox mesylate maintenance dose compositions and methods for using the same |
| WO2008039566A2 (en) | 2006-04-22 | 2008-04-03 | Hollis-Eden Pharmaceuticals, Inc. | Drugs and uses |
| US20080221074A1 (en) | 2006-11-17 | 2008-09-11 | Jaime Flores-Riveros | Drug Screen and Treatment Method |
| US8354396B2 (en) | 2006-11-17 | 2013-01-15 | Harbor Therapeutics, Inc. | Drug identification and treatment method |
| US8217025B2 (en) | 2006-11-17 | 2012-07-10 | Harbor Therapeutics, Inc. | Drug screening and treatment methods |
| US20080153792A1 (en) | 2006-11-17 | 2008-06-26 | Frincke James M | Drug Identification and Treatment Method |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| EA018974B9 (ru) * | 2008-02-05 | 2014-04-30 | Харбор Терапьютикс, Инк. | Твердые лекарственные формы |
| DK2273994T3 (en) * | 2008-04-03 | 2016-02-01 | Neurmedix Inc | PHARMACEUTICAL FORMS OF A MEDICINE |
| CN102046647A (zh) | 2008-06-06 | 2011-05-04 | 哈博生物科学公司 | 制备17-炔基-7-羟基甾族化合物和相关化合物的方法 |
| WO2010036822A1 (en) | 2008-09-24 | 2010-04-01 | Hollis-Eden Pharmaceuticals, Inc. | Patient populations and treatment methods |
| US9310310B2 (en) | 2011-08-26 | 2016-04-12 | 3M Innovative Properties Company | Flowable dry powder composition |
-
2009
- 2009-04-03 DK DK09726748.8T patent/DK2273994T3/en active
- 2009-04-03 HU HUE09726748A patent/HUE028337T2/en unknown
- 2009-04-03 EP EP09726748.8A patent/EP2273994B1/en active Active
- 2009-04-03 US US12/418,559 patent/US8252947B2/en active Active
- 2009-04-03 CN CN2009801121621A patent/CN102215845A/zh active Pending
- 2009-04-03 WO PCT/US2009/039567 patent/WO2009124300A2/en not_active Ceased
- 2009-04-03 AU AU2009231589A patent/AU2009231589B2/en active Active
- 2009-04-03 ES ES09726748.8T patent/ES2562069T3/es active Active
- 2009-04-03 JP JP2011503236A patent/JP2011527986A/ja not_active Withdrawn
- 2009-04-03 PL PL09726748T patent/PL2273994T3/pl unknown
- 2009-04-03 KR KR1020107024458A patent/KR101545300B1/ko active Active
- 2009-04-03 CA CA2728889A patent/CA2728889C/en active Active
- 2009-04-03 PT PT97267488T patent/PT2273994E/pt unknown
-
2012
- 2012-08-01 US US13/563,996 patent/US20120302537A1/en not_active Abandoned
- 2012-08-01 US US13/563,982 patent/US20120296105A1/en not_active Abandoned
-
2014
- 2014-08-14 US US14/459,528 patent/US9555046B2/en active Active
- 2014-08-14 US US14/459,493 patent/US9877972B2/en active Active
- 2014-12-01 JP JP2014242946A patent/JP2015042686A/ja active Pending
-
2016
- 2016-11-10 US US15/348,107 patent/US9850271B2/en active Active
-
2017
- 2017-12-21 US US15/851,523 patent/US20180208623A1/en not_active Abandoned
-
2019
- 2019-10-10 US US16/598,694 patent/US10995112B2/en active Active
-
2021
- 2021-04-26 US US17/240,728 patent/US20220002338A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011527986A5 (https=) | ||
| JP2018520178A5 (https=) | ||
| Layek et al. | Physical and mechanical properties of poly (methyl methacrylate)-functionalized graphene/poly (vinylidine fluoride) nanocomposites: Piezoelectric β polymorph formation | |
| JP2012176975A5 (https=) | ||
| Cao et al. | Fabrication and characterization of novel shape-stabilized synergistic phase change materials based on PHDA/GO composites | |
| JP2012508178A5 (https=) | ||
| JP2014522388A5 (https=) | ||
| JP2012233166A5 (https=) | ||
| JP2012233172A5 (https=) | ||
| JP2011511011A5 (https=) | ||
| JP2015521621A5 (https=) | ||
| JP2012233167A5 (https=) | ||
| JP2012233159A5 (https=) | ||
| JP2018531280A5 (https=) | ||
| JP2016510768A5 (https=) | ||
| JP2015516425A5 (https=) | ||
| JP2016510767A5 (https=) | ||
| Yang et al. | Crystal morphology, crystallization behavior, polymorphic crystalline structure and thermal stability of poly (1, 4-butylene adipate) modulated by a oxalamide derivative nucleating agent | |
| JP2013503145A5 (https=) | ||
| JP2016536321A5 (https=) | ||
| Bahader et al. | Preparation and characterization of poly (vinylidene fluoride) nanocomposites containing amphiphilic ionic liquid modified multiwalled carbon nanotubes | |
| JP2018024683A5 (https=) | ||
| JP2013520412A5 (https=) | ||
| Sun et al. | Synthesis, characterization and application of methyl 3, 5-disulfo-benzoate dipotassium dihydrate as nucleating agent for Poly (L-lactide) | |
| JP2010540440A5 (https=) |